Aging is associated with cognitive impairment, but the underlying mechanisms remain unclear. We have recently reported that the ability of rats to learn a Y-maze conditional discrimination task depends on the function of the glutamate-nitric oxide-cGMP pathway in brain. The aims of the present work were to assess whether the ability of rats to learn this task decreases with age and whether this reduction is associated with a decreased function of the glutamate-nitric oxide-cGMP pathway in brain in vivo, as analyzed by microdialysis in freely moving rats. We show that 7-mo-old rats need significantly more (192 +/- 64%) trials than do 3-mo-old rats to learn the Y-maze task. Moreover, the function of the glutamate-nitric oxide-cGMP pathway is reduced by 60 +/- 23% in 7-mo-old rats compared with 3-mo-old rats. The results reported support the idea that the reduction in the ability to learn the Y-maze task (and likely other types of learning) of mature compared with young rats would be a consequence of reduced function of the glutamate-nitric oxide-cGMP pathway.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216530PMC
http://dx.doi.org/10.1101/lm.541307DOI Listing

Publication Analysis

Top Keywords

function glutamate-nitric
20
glutamate-nitric oxide-cgmp
20
oxide-cgmp pathway
20
pathway brain
12
rats learn
12
learn y-maze
12
rats
9
brain vivo
8
mature compared
8
compared young
8

Similar Publications

Metabolic Recruitment in Brain Tissue.

Annu Rev Physiol

February 2023

NeuroCentre Magendie, INSERM U1215, University of Bordeaux, Bordeaux, France.

Information processing imposes urgent metabolic demands on neurons, which have negligible energy stores and restricted access to fuel. Here, we discuss metabolic recruitment, the tissue-level phenomenon whereby active neurons harvest resources from their surroundings. The primary event is the neuronal release of K that mirrors workload.

View Article and Find Full Text PDF

Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.

J Clin Psychopharmacol

November 2021

Department of Psychiatry, Interdisciplinary Lab of Clinical Neurosciences (LiNC), and Schizophrenia Program (PROESQ), Federal São Paulo University (Unifesp), São Paulo, Brazil.

Background: Schizophrenia is a complex disabling mental disorder, and many patients present poor response to available treatments. Accumulating evidence about the role of the glutamate/nitric oxide pathway in mediating the positive and negative symptoms of schizophrenia suggests potential benefits of drugs that modulate this system. The aim of this study was to test the efficacy of isosorbide mononitrate (ISMN) as an adjunctive therapy for symptomatic outpatients with schizophrenia.

View Article and Find Full Text PDF

Tolerance to alcohol: A critical yet understudied factor in alcohol addiction.

Pharmacol Biochem Behav

May 2021

Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. Electronic address:

Alcohol tolerance refers to a lower effect of alcohol with repeated exposure. Although alcohol tolerance has been historically included in diagnostic manuals as one of the key criteria for a diagnosis of alcohol use disorder (AUD), understanding its neurobiological mechanisms has been neglected in preclinical studies. In this mini-review, we provide a theoretical framework for alcohol tolerance.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore the effects of combining desferrioxamine (DFO) and dextromethorphan (DXM) on Parkinson's disease symptoms in a rat model.
  • By inducing Parkinson's using 6-hydroxydopamine, researchers assessed changes in behavior and neurobiochemical markers, finding that the combination treatment significantly improved motor symptoms and antioxidant enzyme levels while reducing harmful substances in the brain.
  • The findings suggest that DFO and DXM may work together to protect dopamine neurons and mitigate symptoms of Parkinson's by reducing excitotoxicity and inflammation, indicating a potential therapeutic strategy for managing the disease.
View Article and Find Full Text PDF

Pregabalin is the first drug to receive FDA approval for treating diabetic neuropathic pain. This study investigated the neuroprotective effect of pregabalin in an experimental model of diabetic retinopathy and tested some possible mechanisms underlying the putative neuroprotective effect. Male Wistar rats received streptozotocin (45 mg/kg) to induce type 1 diabetes mellitus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!